Recombinant Human Epidermal Growth Factor (rhEGF) is a topical biological agent that mimics the endogenous EGF, a 53-amino acid polypeptide. It is a potent mitogen for epithelial cells, fibroblasts, and keratinocytes, playing a crucial role in wound healing by stimulating cell proliferation, migration, and differentiation. In the Indian market, it is primarily formulated as a gel or cream for topical application in wound management.
Adult: Apply a thin layer (approx. 0.5 gm of gel per 10 sq cm wound area) once or twice daily, or as directed by the physician. The wound should be cleaned and debrided before each application.
Note: 1. Cleanse wound thoroughly with normal saline or prescribed antiseptic. 2. Pat dry gently. 3. Apply a uniform thin layer to cover entire wound bed. 4. Cover with a sterile non-adherent dressing. 5. Wash hands before and after application. Do not use occlusive dressings unless advised.
rhEGF is a ligand for the Epidermal Growth Factor Receptor (EGFR), a transmembrane tyrosine kinase receptor. Binding induces receptor dimerization and autophosphorylation, activating major intracellular signaling cascades (RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways). This leads to increased DNA synthesis, transcription of genes involved in cell cycle progression, and synthesis of proteins and extracellular matrix components essential for tissue repair.
Pregnancy: Category C: Animal reproduction studies have not been conducted. It is not known whether rhEGF can cause fetal harm when used topically. Use only if the potential benefit justifies the potential risk to the fetus. Systemic absorption is minimal.
Driving: No effect. Therapy does not impair mental or physical abilities.
| Topical Corticosteroids (e.g., Betamethasone, Clobetasol) | May antagonize the wound healing and proliferative effects of rhEGF. | Moderate |
| Topical Antiseptics (e.g., Povidone-Iodine, Hydrogen Peroxide) | Concurrent application may inactivate the protein. A time gap of at least 30 minutes between antiseptic wash and rhEGF application is recommended. | Significant |
| Other Topical Growth Factors or Biologicals | No data. Potential for additive effect or interference. Not recommended. | Unknown |
| Systematic Chemotherapeutic Agents (EGFR inhibitors like Cetuximab) | Theoretical antagonism at receptor level. Clinical significance for topical EGF is unknown. | Theoretical |
Same composition (Recombinant Human Epidermal Growth Factor (60mcg/gm)), different brands: